## Kathryn M Ferguson

## List of Publications by Year in descending order

Source: https:/|exaly.com/author-pdf/6066826/publications.pdf
Version: 2024-02-01

1 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 16.8 ..... 949
2005, 7, 301-311.9.7774An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell,
$2003,12,541-552$.An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell,
$2003,12,541-552$.9.7675
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization.
3 Molecular Cell, 2003, 11, 507-517.3.7656
Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochemical Journal, 2000,Structure-Based View of Epidermal Growth Factor Receptor Regulation. Annual Review of Biophysics,2008, 37, 353-373.
7 EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Cell, 2017, 171, 7 683-695.el8.
Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced
Conformational Changes in the Dimer Interface. Molecular and Cellular Biology, 2005, 25, 7734-7742. ..... 2.3 ..... 247
Complex Relationship between Ligand Binding
Receptor. Cell Reports, 2014, 9, 1306-1317.
10 Scratching the surface with the PH domain. Nature Structural and Molecular Biology, 1995, 2, 715-718. ..... 8.2 ..... 59
$11 \begin{aligned} & \text { Molecular Basis for Necitumumab Inhibition of EGFR Variants As } \\ & \text { Resistance. Molecular Cancer Therapeutics, 2018, 17, 521-531. }\end{aligned}$
$11 \begin{aligned} & \text { Molecular Basis for Necitumumab Inhibition of EGFR Variants As } \\ & \text { Resistance. Molecular Cancer Therapeutics, 2018, 17, 521-531. }\end{aligned}$ 4.1 4.1 ..... 45 ..... 45
12 Phosphate Binding Site. Structure, 2015, 23, 352-363. ..... 3.3 ..... 40
27.8 ..... 3613 Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. Nature, 2022, 602, 518-522.Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.7.631Protein Science, 2020, 29, 1331-1344.Dimerization of Tie2 mediated by its membrane-proximal FNIII domains. Proceedings of the NationalAcademy of Sciences of the United States of America, 2017, 114, 4382-4387.7.129
Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1

